Skip to main content
NASDAQ:ZNTL

Zentalis Pharmaceuticals News Headlines

$58.82
+1.23 (+2.14 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$56.63
$59.63
50-Day Range
$37.41
$62.25
52-Week Range
$25.41
$62.79
Volume276,417 shs
Average Volume297,746 shs
Market Capitalization$2.43 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Zentalis Pharmaceuticals (NASDAQ ZNTL) News Headlines Today

SourceHeadline
SVB Leerink Raises Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $64.00SVB Leerink Raises Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $64.00
marketbeat.com - April 19 at 9:08 AM
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Sees Large Volume IncreaseZentalis Pharmaceuticals (NASDAQ:ZNTL) Sees Large Volume Increase
americanbankingnews.com - May 14 at 11:32 AM
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price Up 3%Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price Up 3%
americanbankingnews.com - May 11 at 11:39 AM
Dicerna Pharmaceuticals (DRNA) CEO Doug Fambrough on Q1 2021 Results - Earnings Call TranscriptDicerna Pharmaceuticals (DRNA) CEO Doug Fambrough on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 12:06 AM
Gain Therapeutics, Inc. Reports First Quarter 2021 Financial ResultsGain Therapeutics, Inc. Reports First Quarter 2021 Financial Results
markets.businessinsider.com - May 10 at 7:05 PM
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Down to $57.33Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Down to $57.33
americanbankingnews.com - May 7 at 11:52 AM
Melissa B. Epperly Sells 3,083 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) StockMelissa B. Epperly Sells 3,083 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock
americanbankingnews.com - May 5 at 5:52 PM
Insider Selling: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) COO Sells 8,420 Shares of StockInsider Selling: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) COO Sells 8,420 Shares of Stock
americanbankingnews.com - May 5 at 5:05 PM
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Sells $592,500.00 in StockZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Sells $592,500.00 in Stock
americanbankingnews.com - May 5 at 5:05 PM
Insider Selling: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) CEO Sells 26,794 Shares of StockInsider Selling: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) CEO Sells 26,794 Shares of Stock
americanbankingnews.com - May 5 at 5:05 PM
 Brokerages Expect Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) to Announce -$0.96 Earnings Per Share Brokerages Expect Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) to Announce -$0.96 Earnings Per Share
americanbankingnews.com - May 1 at 12:16 PM
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Sees Unusually-High Trading VolumeZentalis Pharmaceuticals (NASDAQ:ZNTL) Sees Unusually-High Trading Volume
americanbankingnews.com - April 29 at 2:54 PM
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Down to $61.10Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Down to $61.10
americanbankingnews.com - April 28 at 11:42 AM
First Week of ZNTL June 18th Options TradingFirst Week of ZNTL June 18th Options Trading
nasdaq.com - April 27 at 2:08 PM
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Sets New 12-Month High at $62.84Zentalis Pharmaceuticals (NASDAQ:ZNTL) Sets New 12-Month High at $62.84
americanbankingnews.com - April 26 at 2:40 PM
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Sees Strong Trading VolumeZentalis Pharmaceuticals (NASDAQ:ZNTL) Sees Strong Trading Volume
americanbankingnews.com - April 22 at 11:54 AM
Zentalis Enters Clinical Collaboration And Supply Agreement With GSK To Evaluate ZN-c3Zentalis Enters Clinical Collaboration And Supply Agreement With GSK To Evaluate ZN-c3
nasdaq.com - April 12 at 12:21 PM
Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP InhibitorZentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor
finance.yahoo.com - April 12 at 7:20 AM
Zentalis Pharmaceuticals Inc (ZNTL) President & CEO Anthony Y Sun Sold $2.8 million of SharesZentalis Pharmaceuticals Inc (ZNTL) President & CEO Anthony Y Sun Sold $2.8 million of Shares
finance.yahoo.com - April 7 at 11:35 PM
Zentalis Pharma: Charting A Way ForwardZentalis Pharma: Charting A Way Forward
nasdaq.com - April 1 at 8:05 AM
Zentalis Pharmaceuticals Inc.Zentalis Pharmaceuticals Inc.
barrons.com - March 18 at 8:31 AM
Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at the AACR Annual Meeting 2021Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at the AACR Annual Meeting 2021
finance.yahoo.com - March 10 at 7:48 PM
Zentalis Pharmaceuticals Inc (ZNTL) President & CEO Anthony Y Sun Sold $1.1 million of SharesZentalis Pharmaceuticals Inc (ZNTL) President & CEO Anthony Y Sun Sold $1.1 million of Shares
finance.yahoo.com - March 3 at 8:07 PM
Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development CapabilitiesZentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities
finance.yahoo.com - February 25 at 8:02 AM
Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021
finance.yahoo.com - February 24 at 9:09 AM
RSI Alert: Zentalis Pharmaceuticals (ZNTL) Now OversoldRSI Alert: Zentalis Pharmaceuticals (ZNTL) Now Oversold
nasdaq.com - February 11 at 4:10 PM
Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of DirectorsZentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors
finance.yahoo.com - February 10 at 7:36 AM
Zentalis Pharmaceuticals, Inc. (ZNTL)Zentalis Pharmaceuticals, Inc. (ZNTL)
realmoney.thestreet.com - February 6 at 5:25 PM
Why Earnings Season Could Be Great for Zentalis (ZNTL)Why Earnings Season Could Be Great for Zentalis (ZNTL)
finance.yahoo.com - February 4 at 1:15 PM
Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical TrialsZentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials
finance.yahoo.com - January 6 at 10:44 AM
ZNTL Crosses Above Average Analyst TargetZNTL Crosses Above Average Analyst Target
nasdaq.com - December 23 at 12:59 PM
Who Has Been Buying Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares?Who Has Been Buying Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares?
finance.yahoo.com - December 23 at 12:59 PM
Is ZNTL A Good Stock To Buy Now?Is ZNTL A Good Stock To Buy Now?
finance.yahoo.com - December 12 at 11:17 PM
IPO Preview: Olema Pharmaceuticals Starts IPO ProcessIPO Preview: Olema Pharmaceuticals Starts IPO Process
thestreet.com - November 5 at 12:29 AM
What Kind Of Investors Own Most Of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)?What Kind Of Investors Own Most Of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)?
finance.yahoo.com - September 23 at 7:07 PM
Zentalis Pharmaceuticals to Host a Key Opinion Leader Virtual Meeting to Discuss its Investigational WEE1 Inhibitor ZN-c3 and its Potential as a Best-in-Class Treatment for Advanced Solid TumorsZentalis Pharmaceuticals to Host a Key Opinion Leader Virtual Meeting to Discuss its Investigational WEE1 Inhibitor ZN-c3 and its Potential as a Best-in-Class Treatment for Advanced Solid Tumors
finance.yahoo.com - September 11 at 11:32 AM
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor ConferencesZentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - September 10 at 9:43 AM
Zentalis Pharmaceuticals Appoints Alexis Pinto as Chief Legal OfficerZentalis Pharmaceuticals Appoints Alexis Pinto as Chief Legal Officer
finance.yahoo.com - September 1 at 7:23 AM
Zentalis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational UpdateZentalis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Update
finance.yahoo.com - August 13 at 9:35 AM
Zentalis Pharmaceuticals Announces Pricing of Upsized Offering of Common StockZentalis Pharmaceuticals Announces Pricing of Upsized Offering of Common Stock
finance.yahoo.com - July 29 at 10:28 PM
Zentalis Pharmaceuticals Announces Proposed Public Offering of Common StockZentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - July 27 at 6:47 PM
Zentalis Pharmaceuticals Enters into Clinical Collaboration with Eli Lilly and Company to Evaluate its Oral SERD ZN-c5 in Combination with Abemaciclib, a CDK4 and 6 InhibitorZentalis Pharmaceuticals Enters into Clinical Collaboration with Eli Lilly and Company to Evaluate its Oral SERD ZN-c5 in Combination with Abemaciclib, a CDK4 and 6 Inhibitor
finance.yahoo.com - July 27 at 8:45 AM
Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of DirectorsZentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors
finance.yahoo.com - July 1 at 10:12 AM
Zentalis Pharmaceuticals to Present Preclinical Data on ZN-c5 at the Upcoming AACR Virtual Annual Meeting IIZentalis Pharmaceuticals to Present Preclinical Data on ZN-c5 at the Upcoming AACR Virtual Annual Meeting II
finance.yahoo.com - June 15 at 7:53 PM
Is It Too Late to Jump In on Zentalis?Is It Too Late to Jump In on Zentalis?
finance.yahoo.com - June 11 at 9:19 AM
Zentalis Pharmaceuticals to Participate in Jefferies Virtual Healthcare ConferenceZentalis Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 28 at 5:28 PM
Zentalis Pharmaceuticals and Tavros Therapeutics Announce Strategic Platform Collaboration to Discover Next Generation Targeted Small Molecule TherapiesZentalis Pharmaceuticals and Tavros Therapeutics Announce Strategic Platform Collaboration to Discover Next Generation Targeted Small Molecule Therapies
finance.yahoo.com - May 28 at 7:27 AM
Zentalis Pharmaceuticals Announces $20 Million Series A Financing to Establish a Chinese Joint Venture, Zentera TherapeuticsZentalis Pharmaceuticals Announces $20 Million Series A Financing to Establish a Chinese Joint Venture, Zentera Therapeutics
finance.yahoo.com - May 20 at 9:15 AM
Zentalis Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational UpdateZentalis Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Update
finance.yahoo.com - May 15 at 8:52 AM
Zentalis Pharmaceuticals Announces FDA Clearance of IND Application for ZN-d5 for the Treatment of Hematologic MalignanciesZentalis Pharmaceuticals Announces FDA Clearance of IND Application for ZN-d5 for the Treatment of Hematologic Malignancies
finance.yahoo.com - April 30 at 5:16 PM
Zentalis Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesZentalis Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - April 14 at 4:49 PM
This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.